Ind-Swift Laboratories Ltd. benchmarking: Perfomance to industry peers

Financial

	Ind-Swift Lab.	Jagsonpal Pharma	Venus Remedies
Operational Metrics
Pharmaceuticals
Total reactor capacity	700.0 kL	n/a	n/a
DMF Filingsby API	474.0 .	n/a	n/a
R&D as a % of Total Sales	2.9 %	n/a	n/a
Financials
5 yr Average ROE	14.53 %	16.01 %	8.87 %
5yr average Equity Multiplier	2.17	1.27	1.32
5yr Average Asset Turnover Ratio	0.66	1.09	0.96
5yr Avg Net Profit Margin	16.17 %	12.08 %	6.91 %
Price to Book	0.82	4.46	1.66
P/E	4.32	27.56	12.94
5yr Avg Cash Conversion Cycle	15.71 Days	2.39 Days	46.96 Days
Inventory Days	103.91 Days	37.29 Days	75.64 Days
Days Receivable	105.66 Days	15.63 Days	54.28 Days
Days Payable	107.02 Days	59.94 Days	58.86 Days
5yr Average Interest Coverage Ratio	21.19	66.99	396.11
5yr Avg ROCE	12.09 %	18.99 %	8.42 %
5yr Avg Operating Profit Margin	14.94 %	13.23 %	10.14 %
5 yr average Debt to Equity	0.91	0.01	0.08
5yr CAGR Net Profit	n/a	26.54 %	-6.01 %
5yr Average Return on Assets	11.49 %	12.71 %	6.69 %
Shareholdings
Promoter Holding	39.5 %	67.39 %	41.76 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	-2.5 %	-1.32 %	0.0
Change in Mutual Fund Holding (3 Yrs)	0.0	0.0	0.0

	Ind-Swift Lab.	Jagsonpal Pharma	Venus Remedies
Product Wise Break-Up	Product Wise Break-Up Pharmaceutical 100.0	Product Wise Break-Up Pharmaceutical 0 Others 100	Product Wise Break-Up Pharmaceutical 0 Others 100
Location Wise Break-Up	Location Wise Break-Up India 27.72 Domestic 0 Others 72.28	Location Wise Break-Up India 0 India 98.7 Others 1.3	Location Wise Break-Up India 33.0 Domestic 0 Others 67.0
Operating Profit Break-Up	Operating Profit Break-Up India 18.87 Others 81.13	-	-
Asset Break-Up	Asset Break-Up India 67.55 Others 32.45	-	-